Physics and AI Driven Precision Engineering of Novel Drugs

Health + Time : Priceless

We Engineer New Treatments Atom by Atom

To help you live healthier, longer

First-in-Class Drug Candidates to Change the Standard of Care for Every Disease We Address
More about our pipeline
Recent News
Our stories
Unlocking a Universe of Drug Candidates
Verseon's hybrid physics- and AI-based platform reveals possibilities far outside the Pharma industry's compound libraries
May 4, 2023
Dreaming Up Drugs No One Has Ever Seen
Verseon's physics- and AI-based drug discovery platform is expanding the frontiers of medicine
FEBRUARY 15, 2023
Disruptors Plan a New Dawn for Healthcare Technology
The Business Influencer describes how Verseon’s drug discovery platform is systematically tackling humanity’s major killers
FEBRUARY 3, 2023
What Will it Take for AI to Live Up to its Hype?
Adityo Prakash, CEO of Verseon, discusses how the data currently available to the pharma industry and other challenges limit AI’s ability to help discover novel drugs
JANUARY 31, 2023
Small Data, Big Ambitions
Verseon's combination of physics-based molecular modeling and Extreme Machine Learning promises multiple treatment options for patients who currently have none
JANUARY 11, 2023
Verseon’s New Oral Anticoagulant Drug Candidates Demonstrate Lower Bleeding Risk
Verseon has developed candidates for a next-generation oral anticoagulant that have the potential to prevent unwanted clots while preserving the body’s ability to stop excessive bleeding
December 15, 2022
Preventing Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding
Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry
DECEMBER 14, 2022
Is AI just hype or a real revolution in pharma? It’s complicated
Verseon's CEO Adityo Prakash discusses the challenges and opportunities facing AI in drug discovery
NOVEMBER 17, 2022
Unlocking a Universe of Drug Candidates
Verseon's hybrid physics- and AI-based platform reveals possibilities far outside the Pharma industry's compound libraries
May 4, 2023
Dreaming Up Drugs No One Has Ever Seen
Verseon's physics- and AI-based drug discovery platform is expanding the frontiers of medicine
FEBRUARY 15, 2023
Disruptors Plan a New Dawn for Healthcare Technology
The Business Influencer describes how Verseon’s drug discovery platform is systematically tackling humanity’s major killers
FEBRUARY 3, 2023
What Will it Take for AI to Live Up to its Hype?
Adityo Prakash, CEO of Verseon, discusses how the data currently available to the pharma industry and other challenges limit AI’s ability to help discover novel drugs
JANUARY 31, 2023
Small Data, Big Ambitions
Verseon's combination of physics-based molecular modeling and Extreme Machine Learning promises multiple treatment options for patients who currently have none
JANUARY 11, 2023
Verseon’s New Oral Anticoagulant Drug Candidates Demonstrate Lower Bleeding Risk
Verseon has developed candidates for a next-generation oral anticoagulant that have the potential to prevent unwanted clots while preserving the body’s ability to stop excessive bleeding
December 15, 2022
Preventing Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding
Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry
DECEMBER 14, 2022
Is AI just hype or a real revolution in pharma? It’s complicated
Verseon's CEO Adityo Prakash discusses the challenges and opportunities facing AI in drug discovery
NOVEMBER 17, 2022
More News
Changing everything the world can expect from 21st Century Medicine
Continue to Company